Neurogene Inc.
NGNE
$15.00
$1.9715.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 925.00K | 925.00K | 925.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 925.00K | 925.00K | 925.00K | -- | -- |
| Cost of Revenue | -40.96M | 14.16M | 9.48M | 4.06M | 897.00K |
| Gross Profit | 41.89M | -13.23M | -8.55M | -4.06M | -897.00K |
| SG&A Expenses | 22.61M | 19.00M | 16.72M | 13.68M | 11.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.53M | 76.65M | 69.69M | 61.23M | 55.58M |
| Operating Income | -82.61M | -75.73M | -68.77M | -61.23M | -55.58M |
| Income Before Tax | -75.14M | -53.25M | -47.61M | -40.98M | -36.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.14 | -53.25 | -47.61 | -40.98 | -36.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.14M | -53.25M | -47.61M | -40.98M | -36.32M |
| EBIT | -82.61M | -75.73M | -68.77M | -61.23M | -55.58M |
| EBITDA | -79.36M | -72.45M | -65.47M | -57.92M | -52.29M |
| EPS Basic | -4.29 | 78.14 | 46.67 | 21.07 | -6.20 |
| Normalized Basic EPS | -2.68 | -15.63 | -35.30 | -51.30 | -68.35 |
| EPS Diluted | -4.29 | -0.26 | -31.73 | -57.32 | -84.60 |
| Normalized Diluted EPS | -2.68 | -2.55 | -22.22 | -38.22 | -55.27 |
| Average Basic Shares Outstanding | 70.27M | 51.44M | 34.93M | 18.44M | 1.97M |
| Average Diluted Shares Outstanding | 70.27M | 68.10M | 51.59M | 35.10M | 18.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |